Skip to Main Content

Paper Details

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Clin Cancer Res
101
2014
-, ABL1, ABL1 tyrosine kinase, AKT, AML, AML cell lines, BCR, CML, CML and AML cell lines, CML cells, K562 cells, OP449, PP2A, SET, SET oncoprotein, SET protein, STAT5, acute myeloid leukemia, blastic phase disease, chronic myeloid leukemia, chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) cell lines, human, human HL-60, human leukemia cells, leukemia, mice, murine, myeloid leukemia, patient, patients, primary CD34(+) CML cells, primary patient samples, primary samples, protein phosphatase 2A, tyrosine, tyrosine kinase
Author NameAffiliation
Anupriya AgarwalAuthors' Affiliations: Knight Cancer Institute Division of Hematology & Medical Oncology Departments of Cell and Developmental Biology and Molecular and Medical Genetics, Oregon Health and Science University Howard Hughes Medical Institute, Oregon Oncotide Pharmaceuticals, Research Triangle Park Duke University Medical Center, Center for Applied Medical Research (CIMA), University of Navarra
  • 1 - 1

Datasets

Release 1.2